» Articles » PMID: 35629260

Constipation Symptoms in Multiple System Atrophy Using Rome Criteria and Their Impact on Personalized Medicine

Overview
Journal J Pers Med
Date 2022 May 28
PMID 35629260
Authors
Affiliations
Soon will be listed here.
Abstract

Constipation is one of the most common non-motor symptoms in multiple system atrophy (MSA); however, it has not been evaluated according to the standard diagnostic criteria for constipation in patients with MSA. We evaluated the characteristics of constipation in patients with MSA by using Rome criteria (Rome III), which has been validated and the widely used for gastrointestinal disorders. Fifty-one patients with MSA (29 female) were enrolled in the study. Based on the Rome III criteria, constipation was diagnosed in 29 patients (56.9%); irritable bowel syndrome was not detected. Thirty-seven patients (72.5%) were aware of their constipation. The most common constipation symptom was the sensation of anorectal obstruction (68.6%). Patients’ self-awareness of constipation was most strongly correlated to the sensation of incomplete evacuation (odds ratio: 7.377, 95% confidence interval: 1.402−38.817). The number of constipation-related symptoms was correlated with the total levodopa equivalent dose (p < 0.05). Rome criteria, which can detect various constipation symptoms, are useful for evaluating constipation in MSA, and these findings may greatly impact personalized medicine.

Citing Articles

Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome.

Bicknell B, Liebert A, Borody T, Herkes G, McLachlan C, Kiat H Int J Mol Sci. 2023; 24(11).

PMID: 37298527 PMC: 10253993. DOI: 10.3390/ijms24119577.


Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy.

Hu W, Cao L, Yin J, Zhao X, Piao Y, Gu W Front Neurol. 2023; 13:1081219.

PMID: 36756345 PMC: 9901543. DOI: 10.3389/fneur.2022.1081219.


Lifelong constipation in Parkinson's disease and other clinically defined alpha-synucleinopathies: A population-based study in Southeast Minnesota.

Camerucci E, Mullan A, Bower J, Bharucha A, Turcano P, Stang C Parkinsonism Relat Disord. 2023; 107:105244.

PMID: 36630736 PMC: 10262204. DOI: 10.1016/j.parkreldis.2022.105244.

References
1.
Astarloa R, Mena M, Sanchez V, de la Vega L, de Yebenes J . Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol. 1992; 15(5):375-80. DOI: 10.1097/00002826-199210000-00004. View

2.
Shen T, Yue Y, He T, Huang C, Qu B, Lv W . The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis. Front Aging Neurosci. 2021; 13:636545. PMC: 7907649. DOI: 10.3389/fnagi.2021.636545. View

3.
Sakakibara R . Gastrointestinal dysfunction in movement disorders. Neurol Sci. 2021; 42(4):1355-1365. DOI: 10.1007/s10072-021-05041-4. View

4.
Romano S, Savva G, Bedarf J, Charles I, Hildebrand F, Narbad A . Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021; 7(1):27. PMC: 7946946. DOI: 10.1038/s41531-021-00156-z. View

5.
Lai S, Liao K, Lin C, Sung F . Irritable bowel syndrome correlates with increased risk of Parkinson's disease in Taiwan. Eur J Epidemiol. 2014; 29(1):57-62. DOI: 10.1007/s10654-014-9878-3. View